Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Go back to Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Diversified Corporate Resources, Inc. (NASDAQ: IRD) Delayed: 3.59 -0.23 (6.02%)
Previous Close $3.82    52 Week High $0.02 
Open $3.79    52 Week Low $0.02 
Day High $3.83    P/E N/A 
Day Low $3.56    EPS $0.00 
Volume 335,423